Oppenheimer Asset Management Inc. Has $28.47 Million Position in Kenvue Inc. (NYSE:KVUE)

Oppenheimer Asset Management Inc. decreased its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 0.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,333,315 shares of the company’s stock after selling 8,119 shares during the period. Oppenheimer Asset Management Inc. owned 0.07% of Kenvue worth $28,466,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Grove Bank & Trust boosted its holdings in shares of Kenvue by 438.4% during the 4th quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock worth $25,000 after buying an additional 947 shares in the last quarter. Geneos Wealth Management Inc. acquired a new stake in Kenvue in the fourth quarter worth $29,000. Ashton Thomas Securities LLC acquired a new position in shares of Kenvue during the third quarter valued at about $35,000. Fortitude Family Office LLC boosted its position in shares of Kenvue by 106.6% during the 4th quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock worth $32,000 after purchasing an additional 777 shares in the last quarter. Finally, Versant Capital Management Inc increased its position in Kenvue by 300.8% in the 4th quarter. Versant Capital Management Inc now owns 1,920 shares of the company’s stock valued at $41,000 after buying an additional 1,441 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Stock Performance

KVUE stock opened at $23.22 on Thursday. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The firm has a market cap of $44.52 billion, a PE ratio of 43.81, a P/E/G ratio of 2.62 and a beta of 1.45. The business has a 50 day moving average of $21.36 and a 200-day moving average of $22.23. Kenvue Inc. has a 12-month low of $17.67 and a 12-month high of $24.46.

Kenvue (NYSE:KVUE) last announced its earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. As a group, sell-side analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th were given a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.53%. The ex-dividend date was Wednesday, February 12th. Kenvue’s dividend payout ratio is currently 154.72%.

Analyst Upgrades and Downgrades

A number of brokerages have commented on KVUE. Piper Sandler raised their price objective on Kenvue from $24.00 to $27.00 and gave the company an “overweight” rating in a research note on Monday. Barclays reduced their price target on shares of Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a research report on Friday, January 17th. Royal Bank of Canada restated a “sector perform” rating and set a $24.00 price objective on shares of Kenvue in a report on Monday, February 3rd. Citigroup dropped their price objective on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 15th. Finally, UBS Group lowered their target price on shares of Kenvue from $23.00 to $21.00 and set a “neutral” rating on the stock in a report on Friday, February 7th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $23.08.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.